Browse drugs

…nsporter 2 inhibitors, and insulin, as well as length of use of metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 inhi…

…s Affairs users with type 2 diabetes who started treatment with GLP-1RAs (n=132 551) or sulfonylureas (n=201 136), followed up for three…

… among the GLP-1RA group compared with the sulfonylureas group. GLP-1RA=glucagon-like peptide-1 receptor agonistsDiscussionIn this nati…

…lin and SGLT2 inhibitors, while DPP-4 inhibitors clustered with metformin ( figure 1). Heatmapping confirmed strong phenotype-specific en…

… continuity, to maintain the cardioprotective effects seen with GLP-1RAs. Future research should focus on the generalisability of these …

…ssociation. One potential explanation is the high prevalence of statin use among patients, which may have attenuated the variability i…

… challenge globally. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in weight loss; however…

…ever, these studies did not employ suitable active comparators. Metformin is often prescribed as first-line therapy in T2DM management, w…

…ncluding effects of SGLT-2 inhibitors, GLP-1RAs, finerenone and tirzepatide.Systematic review registration PROSPERO number: CRD42022325948.…

…Glucagon-like peptide 1 receptor agonists (GLP-1RAs) improve glycaemic control,1 promote weight loss,2 delay progre…

…5% B, and 29% E. Controls were comparable. Patients receiving a GLP-1RAs had significantly lower risk of exacerbations (specific IRR 0.8…

…d significantly after intervention (−2.0% per quarter; p=0.02). Insulin prescribing rates did not change throughout the study period. T…